0 194

Cited 3 times in

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

Authors
 Harry D. Bear  ;  Gong Tang  ;  Priya Rastogi  ;  Charles E. Geyer Jr.  ;  Christine K. Zoon  ;  Kelley M. Kidwell  ;  André Robidoux  ;  Luis Baez-Diaz  ;  Adam M. Brufsky  ;  Rita S. Mehta  ;  Louis Fehrenbacher  ;  James A. Young  ;  Francis M. Senecal  ;  Rakesh Gaur  ;  Richard G. Margolese  ;  Paul T. Adams  ;  Howard M. Gross  ;  Joseph P. Costantino  ;  Soonmyung Paik  ;  Sandra M. Swain  ;  Eleftherios P. Mamounas  ;  Norman Wolmark 
Citation
 ANNALS OF SURGICAL ONCOLOGY, Vol.24(7) : 1853-1860, 2017 
Journal Title
 ANNALS OF SURGICAL ONCOLOGY 
ISSN
 1068-9265 
Issue Date
2017
MeSH
Anthracyclines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects* ; Bevacizumab/administration & dosage ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery* ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Mammaplasty/adverse effects ; Mastectomy/adverse effects* ; Prognosis ; Prospective Studies ; Surgical Wound Infection/etiology* ; Survival Rate ; Taxoids/administration & dosage
Keywords
Breast Cancer ; Bevacizumab ; Docetaxel ; Surgical Complication ; Breast Reconstruction
Abstract
BACKGROUND: NRG Oncology/NSABP trial B-40 tested the impact of adding bevacizumab (bev) to neoadjuvant chemotherapy for operable breast cancer. Secondary endpoints included rates of surgical complications after surgery in patients who did or did not receive bev. METHODS: A total of 1206 women with HER2-negative operable breast cancer were randomly assigned to receive one of three different docetaxel-plus-anthracycline-based regimens, without or with bev (15 mg/kg every 3 weeks) for the first 6 of 8 cycles and for 10 doses postoperatively. Surgical complications were assessed from date of surgery through 24 months following study entry. RESULTS: Early surgical complications were significantly more frequent in the bev group (25.4 vs. 18.9%; trend test p = 0.008), but most were grade 1-2. Early noninfectious wound dehiscences were infrequent and not significantly different (5.4 vs. 3.1%; trend test p = 0.15). Long-term noninfectious wound complications were significantly higher for patients receiving bev (11.8 vs. 5.1%; trend test p = 0.0007), but the incidence of grade ≥3 wound dehiscence was low in both groups (<1%). Among 193 patients undergoing expander or implant reconstructions, 19 (19.6%) of 97 in the bev-receiving group versus 10 (10.4%) of 96 in the non-bev group had grade ≥3 complications (Pearson, p = 0.11). CONCLUSIONS: Overall, adding bev increased surgical complications, but most serious complications were not significantly increased. In particular, the need for surgical intervention in patients undergoing breast reconstruction with prosthetic implants was higher with bev but was not statistically significantly different. With precautions, bev can be used safely perioperatively in patients undergoing surgery for breast cancer.
Full Text
https://link.springer.com/article/10.1245%2Fs10434-016-5662-9
DOI
10.1245/s10434-016-5662-9
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
Paik, Soon Myung(백순명) ORCID logo https://orcid.org/0000-0001-9688-6480
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161119
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links